A comparative study of Re-HEDP, Re-HEDP, Sm-EDTMP and Sr in the treatment of painful skeletal metastases

Nuclear Medicine Communications

Volumn 28, Issue 8, 2007, Pages 623-630

  Liepe, Knut ^a   Kotzerke, Joerg ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Bone metastases; Rhenium 186 HEDP; Rhenium 188 HEDP; Samarium 153 EDTMP; Strontium 89

Indexed keywords

1,1 HYDROXYETHYLIDENEDIPHOSPHONATE RE 186; 1,1 HYDROXYETHYLIDENEDIPHOSPHONATE RE 188; ETHYLENEDIAMINE N,N,N',N' TETRAKIS METHYLENEPHOSPHONIC ACID SM 153; RADIOPHARMACEUTICAL AGENT; STRONTIUM 89; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANTINOCICEPTION; ARTICLE; BLOOD CELL COUNT; BONE MARROW; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; KARNOFSKY PERFORMANCE STATUS; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PAIN ASSESSMENT; PAIN THRESHOLD; PROSTATE CANCER; QUALITY OF LIFE; QUESTIONNAIRE; THERAPY EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANALGESICS, NON-NARCOTIC; BONE MARROW; BONE NEOPLASMS; BREAST NEOPLASMS; ETIDRONIC ACID; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PAIN; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIOPHARMACEUTICALS; STRONTIUM; TREATMENT OUTCOME;

EID: 34447545672     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32825a6adc     Document Type: Article

References (49)

1. Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore MJ, et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 2003; 21:3335-3342.
2. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94:1458-1468.
3. McEwan AJ. Palliative therapy with bone seeking radiopharmaceuticals. Cancer Biother Radiopharm 1998; 13:413-426.
4. Debes JD, Tindall DJ. The role of androgens and the androgen receptor in prostate cancer. Cancer Lett 2002; 187:1-7.
5. Gilligan T, Kantoff PW. Chemotherapy for prostate cancer. Urology 2002; 60:94-100; discussion 100.
6. Steenland E, Leer JW, van Houwelingen H, Post WJ, van den Hont WB, Kievit J, et al. The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. Radiother Oncol 1999; 52:101-109.
7. Arcangeli G, Giovinazzo G, Saracino B, D'Angelo L, Giannarelli D, Micheli A. Radiation therapy in the management of symptomatic bone metastases: the effect of total dose and histology on pain relief and response duration. Int J Radiat Oncol Biol Phys 1998; 42:1119-1126.
8. Lewington VJ. Targeted radionuclide therapy for bone metastases. Eur J Nucl Med 1993; 20:66-74.
9. Nielsen OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management policy. J Clin Oncol 1991; 9:509-524.
10. Serafini AN. Current status of systemic intravenous radiopharmaceuticals for the treatment of painful metastatic bone disease. Int J Radiat Oncol Biol Phys 1994; 30:1187-1194.
11. Enrique O, Zhonyun P, Prma EP, Pusuwan P, Ricobona G, Tian JH, et al. Efficacy and toxicity of Sm-153 EDTMP in the palliative treatment of painful bone metastases. World J Nucl Med 2002; 1:21-27.
12. Liepe K, Kropp J, Runge R, Kotzerke J. Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases. Br J Cancer 2003; 89:625-629.
13. Liepe K, Runge R, Kotzerke J. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain. J Cancer Res Clin Oncol 2005; 131:60-66.
14. Liepe K, Runge R, Kotzerke J. Systemic radionuclide therapy in pain palliation. Am J Hosp Palliat Care 2005; 22:457-464.
15. Blake GM, Gray JM, Zivanovic MA, McEwan AJ, Fleming JS, Ackery DM. Strontium-89 radionuclide therapy: a dosimetric study using impulse response function analysis. Br J Radiol 1987; 60:685-692.
16. Porter AT, Davis LP. Systemic radionuclide therapy of bone metastases with strontium-89. Oncology (Huntingt) 1994; 8:93-96; discussion 96, 99-101.
17. Hosain F, Spencer RP. Radiopharmaceuticals for palliation of metastatic osseous lesions: biologic and physical background. Semin Nucl Med 1992; 22:11-16.
18. Robinson RG, Preston DF, Schiefelbein M, Baxter KG. Strontium 89 therapy for the palliation of pain due to osseous metastases. Jama 1995; 274:420-424.
19. Maxon 3rd HR, Schroder LE, Hertzberg VS, Thomas SR, Englaro EE, Samaratunga R, et al. Rhenium-186(Sn) HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo. J Nucl Med 1991; 32:1877-1881.
20. de Klerk JM, Zonnenberg BA, van het Schip AD, van Dijk A, Han SH, Quirihnen JM, et al. Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer. Eur J Nucl Med 1994; 21:1114-1120.
21. Tian JH, Zhang JM, Hou QT, Oyang QH, Wang JM, Luan ZS, et al. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. Eur J Nucl Med 1999; 26:2-7.
22. Maxon 3rd HR, Schroder LE, Washburn LC, Thomas SR, Samaratunga RC, Biniakiewicz D, et al. Rhenium-188(Sn)HEDP for treatment of osseous metastases. J Nucl Med 1998; 39:659-663.
23. Palmedo H, Guhlke S, Bender H, Sartor J, Schoeneich G, Risse J, et al. Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases. Eur J Nucl Med 2000; 27:123-130.
24. Palmedo H, Manka-Waluch A, Albers P, Schmidt-Wolf IG, Reinhardt M, Ezziddin S, et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol 2003; 21:2869-2875.
25. Lin WY, Lin CP, Yeh SJ, Hsieh BT, Tsai ZT, Ting G, et al. Rhenium-188 hydroxyethylidene diphosphonate: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases. Eur J Nucl Med 1997; 24:590-595.
26. Scott J, Huskisson EC. Graphic representation of pain. Pain 1976; 2:175-184.
27. Mor V, Laliberte L, Morris JN, Wiemann M. The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer 1984; 53:2002-2007.
28. World Health Organization. Cancer Pain Relief and Palliative Care. Report of a WHO committee. World Health Organ Technical Report Series. Geneva: World Health Organization; 1990.
29. Pecher P. Biological investigation with radioactive calcium and strontium. Preliminary report on the use of radioactive strontium in the treatment of metastatic bone cancer. University of California Publications in Pharmacology 1942; 2:117-149.
30. 117mSn(4+)diethylenetriaminepentaacetic acid for radionuclide therapy of bone cancer. J Nucl Med 2000; 41:2043-2050.
31. Maxon 3rd HR, Schroder LE, Thomas SR, Hertzberg VS, Deutsch EA, Scher HI, et al. Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer. Radiology 1990; 176:155-159.
32. Bayouth JE, Macey DJ, Kasi LP, Fossella FV. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. J Nucl Med 1994; 35:63-69.
33. 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases. J Nucl Med 2003; 44:953-960.
34. Serafini AN. Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases. Cancer Suppl 2000; 88:2934-2939.
35. 153Sm-EDTMP for bone pain palliation in skeletal metastases. Eur J Nucl Med Mol Imaging 2004; 31:S171-S178.
36. de Klerk JM, van het Schip AD, Zonnenberg BA, van Dijk A, Stokkel MP, Han SH, et al. Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations. J Nucl Med 1994; 35:1423-1428.
37. Turner JH, Martindale AA, Sorby P, Hetherington EL, Fleay RF, Hoffman RF, Claringbold PG. Samarium-153 EDTMP therapy of disseminated skeletal metastasis. Eur J Nucl Med 1989; 15:784-795.
38. Liepe K, Hliscs R, Kropp J, Gruning T, Runge R, Koch R, et al. Rhenium-188-HEDP in the palliative treatment of bone metastases. Cancer Biother Radiopharm 2000; 15:261-265.
39. Dafermou AF, Colamussi PF, Giganti MF, Cittanti CF, Bestagno MF, Piffanelli A. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med 2001; 28:788-798.
40. Kraeber-Bodere F, Campion L, Rousseau C, Bourdin S, Chatal JF, Resche I. Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement. Eur J Nucl Med 2000; 27:1487-1493.
41. 153Sm-EDTMP in patients with painful bone metastases of breast cancer]. Sichuan Da Xue Xue Bao Yi Xue Ban 2003; 34:716-718.
42. Li S, Liu J, Zhang H, Tian M, Wang J, Zheng X. Rhenium-188 HEDP to treat painful bone metastases. Clin Nucl Med 2001; 26:919-922.
43. Zhang H, Tian M, Li S, Liu J, Tanada S, Endo K. Rhenium-188-HEDP therapy for the palliation of pain due to osseous metastases in lung cancer patients. Cancer Biother Radiopharm 2003; 18:719-726.
44. Schmeler K, Bastin K. Strontium-89 for symptomatic metastatic prostate cancer to bone: recommendations for hospice patients. Hosp J 1996; 11:1-10.
45. Roudier MP, Vesselle H, True LD, Higano CS, Ott SM, King SH, Vessella RL. Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. Clin Exp Metastasis 2003; 20:171-180.
46. Pecherstorfer M, Schilling T, Janisch S, Woloszczuk W, Baumgartner G, Ziegler R, Ogris E. Effect of clodronate treatment on bone scintigraphy in metastatic breast cancer. J Nucl Med 1993; 34:1039-1044.
47. Marcus CS, Saeed S, Mlikotic A, Mishkin F, Pham HL, Javellana T, et al. Lack of effect of a bisphosphonate (pamidronate disodium) infusion on subsequent skeletal uptake of Sm-153 EDTMP. Clin Nucl Med 2002; 27:427-430.
48. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001; 357:336-341.
49. 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 2002; 43:79-86.